JPH0995421A - Beautifier for external use - Google Patents
Beautifier for external useInfo
- Publication number
- JPH0995421A JPH0995421A JP8179712A JP17971296A JPH0995421A JP H0995421 A JPH0995421 A JP H0995421A JP 8179712 A JP8179712 A JP 8179712A JP 17971296 A JP17971296 A JP 17971296A JP H0995421 A JPH0995421 A JP H0995421A
- Authority
- JP
- Japan
- Prior art keywords
- placenta extract
- pigmentation
- beautifier
- external use
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002826 placenta Anatomy 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims description 19
- 230000002087 whitening effect Effects 0.000 claims description 19
- 229920002567 Chondroitin Polymers 0.000 claims description 6
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 6
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 18
- 230000019612 pigmentation Effects 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 11
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 238000007796 conventional method Methods 0.000 abstract description 8
- 241000283690 Bos taurus Species 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract description 4
- 206010014970 Ephelides Diseases 0.000 abstract description 3
- 208000003351 Melanosis Diseases 0.000 abstract description 3
- 150000002148 esters Chemical class 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 3
- 239000006210 lotion Substances 0.000 abstract description 3
- 230000002378 acidificating effect Effects 0.000 abstract description 2
- 239000011248 coating agent Substances 0.000 abstract description 2
- 239000006071 cream Substances 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 235000015110 jellies Nutrition 0.000 abstract description 2
- 239000000865 liniment Substances 0.000 abstract description 2
- 239000002674 ointment Substances 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 230000001180 sulfating effect Effects 0.000 abstract description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 abstract 1
- 239000008274 jelly Substances 0.000 abstract 1
- 229940040145 liniment Drugs 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- -1 polyoxyethylene Polymers 0.000 description 6
- 239000004378 Glycyrrhizin Substances 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 5
- 229960004949 glycyrrhizic acid Drugs 0.000 description 5
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 5
- 235000019410 glycyrrhizin Nutrition 0.000 description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 5
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 5
- 229940032094 squalane Drugs 0.000 description 5
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- XKMYWNHZAQUEPY-YZGJEOKZSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 12-hydroxyoctadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC(O)CCCCCC)C1 XKMYWNHZAQUEPY-YZGJEOKZSA-N 0.000 description 4
- 229940067596 butylparaben Drugs 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、コンドロイチン多硫酸
エステルおよびプラセンタエキスを有効成分とする色素
沈着抑制効果に優れた美白外用剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a whitening agent for external use, which contains chondroitin polysulfate and placenta extract as active ingredients and has an excellent effect of suppressing pigmentation.
【０００２】[0002]
【従来の技術】しみ、そばかす、日焼け後などの肌への
色素沈着の発症機構は未だ明確にはされていないが、紫
外線による肌の刺激、角化の遅延などが色素沈着に深く
関与していると考えられている。これら肌への色素沈着
は加齢に伴い発生し、重大な肌の悩みとなっている。そ
のため、肌への色素沈着を抑制する薬剤が強く望まれて
おり、これまで多くの薬剤が開発されてきた。しかし、
これまで開発されてきた薬剤は効果、安全性および安定
性のすべてを満足するものはなかった。例えばビタミン
Ｃは安定性に難があるために、外用製剤では使用が難し
い。また、ハイドロキノン、ビタミンＡ酸などは、ある
程度の効果はあるものの安全性が確保されておらず美白
外用剤に使用するには問題がある。さらにビタミンＣ誘
導体、アルブチン、プラセンタエキスなどは、安全性は
確保できるが効果が満足できない。このように、肌への
色素沈着の抑制を目的とした薬剤については、効果、安
全性および安定性のすべてを満足する美白外用剤は知ら
れていないのが現状である。BACKGROUND OF THE INVENTION Although the mechanism of pigmentation on the skin such as spots, freckles and after sunburn has not been clarified yet, skin irritation by ultraviolet rays, delay of keratinization, etc. are deeply involved in pigmentation. Are believed to be present. Pigmentation on these skins occurs with aging and is a serious skin problem. Therefore, a drug that suppresses pigmentation on the skin has been strongly desired, and many drugs have been developed so far. But,
None of the drugs developed so far satisfy all of the effects, safety and stability. For example, vitamin C is difficult to use in external preparations because of its poor stability. Further, although hydroquinone and vitamin A acid have some effects, their safety is not ensured and there is a problem in using them as a whitening external preparation. Furthermore, vitamin C derivatives, arbutin, placenta extract and the like can secure safety but cannot satisfy the effect. As described above, as for a drug intended to suppress pigmentation on the skin, there is currently no known whitening external preparation satisfying all of the effects, safety and stability.
【０００３】[0003]
【発明が解決しようとする課題】本発明の目的は、美白
メカニズムの異なる、安全な素材を併用することによっ
て安全性を確保し、かつ色素沈着抑制効果を向上した美
白外用剤を提供することにある。SUMMARY OF THE INVENTION An object of the present invention is to provide a whitening agent for external use, in which the safety is ensured by the combined use of safe materials having different whitening mechanisms and the pigmentation suppressing effect is improved. is there.
【０００４】[0004]
【課題を解決するための手段】本発明者らは、色素沈着
を抑制する物質を鋭意検討した結果、コンドロイチン多
硫酸エステルとプラセンタエキスを同時に配合した美白
外用剤が、従来の美白外用剤に比較し色素沈着抑制効果
に優れ、しかも安全性は変わらないことを見いだし本発
明を完成した。すなわち本発明はコンドロイチン多硫酸
エステルおよびプラセンタエキスを配合することを特徴
とする美白外用剤である。Means for Solving the Problems As a result of intensive investigations by the present inventors on a substance that suppresses pigmentation, a whitening external preparation containing chondroitin polysulfate and a placenta extract at the same time was compared with a conventional whitening external preparation. The present invention has been completed by finding that the pigmentation suppression effect is excellent and the safety is not changed. That is, the present invention is a whitening agent for external use characterized by containing chondroitin polysulfate and placenta extract.
【０００５】本発明に用いられるコンドロイチン多硫酸
エステル（以下ＣＰＳと略称する。）は、コンドロイチ
ン硫酸をさらに硫酸化した半合成の酸性ムコ多糖であ
り、コンドロイチン硫酸とは異なるグリコザミノグリカ
ンである。このものは特公昭６２−４３６２号公報に皮
膚の保湿剤としての記載はあるが、美白効果を増強する
効果は知られていなかった。また、特開昭５９−１１６
２０４号公報にはムコ多糖類、可溶性エラスチンおよび
胎盤抽出エキスを配合させた皮膚及び毛髪化粧料の記載
があるが、同公報にはムコ多糖類としてＣＰＳは記載さ
れておらず、また作用効果の点でも美白効果については
記載されていない。The chondroitin polysulfate ester (hereinafter abbreviated as CPS) used in the present invention is a semisynthetic acidic mucopolysaccharide obtained by further sulfating chondroitin sulfate, and is a glycozaminoglycan different from chondroitin sulfate. This compound is described as a skin moisturizer in Japanese Examined Patent Publication No. 62362/1987, but the effect of enhancing the whitening effect was not known. Also, JP-A-59-116
No. 204 publication describes a skin and hair cosmetic composition containing a mucopolysaccharide, soluble elastin and a placenta extract, but the publication does not describe CPS as a mucopolysaccharide, and also has a beneficial effect. The whitening effect is not described even in the point.
【０００６】本発明の美白外用剤の色素沈着抑制効果
は、紫外線による皮膚中プロスタグランジンＥ２の産生
を抑制し、これまで知られていたチロジナーゼ阻害効果
による直接的なメラニン産生抑制効果と異なる化学伝達
物質を介する細胞間相互作用を遮断することにより色素
沈着を抑制すると推定される。[0006] The pigmentation-inhibiting effect of the topical whitening agent of the present invention is different from the direct melanin production-inhibiting effect due to the thyrodinase-inhibiting effect which has hitherto been known, by suppressing the production of prostaglandin E2 in the skin by ultraviolet rays. It is presumed that pigmentation is suppressed by blocking cell-cell interaction via a transmitter.
【０００７】[0007]
【発明の実施の形態】本発明に用いるプラセンタエキス
とは、ヒト胎盤抽出液またはウシ胎盤抽出液を指し、常
法にしたがって得られたものを用いる。BEST MODE FOR CARRYING OUT THE INVENTION The placenta extract used in the present invention refers to a human placenta extract or a bovine placenta extract, which is obtained by a conventional method.
【０００８】ＣＰＳの配合量は、美白外用剤全体の０．
０１〜５．０重量％、好ましくは０．０５〜２．０重量
％である。また、プラセンタエキスは美白外用剤中に
０．１〜２０．０重量％、好ましくは１．０〜１０．０
重量％配合する。The amount of CPS added is 0.
It is from 01 to 5.0% by weight, preferably from 0.05 to 2.0% by weight. In addition, the placenta extract is 0.1 to 20.0% by weight, preferably 1.0 to 10.0 in the whitening external preparation.
% By weight.
【０００９】本発明の美白外用剤には、ＣＰＳおよびプ
ラセンタエキスの他に化粧品、医薬部外品、医薬品など
の皮膚外用剤に用いられている通常の成分および基剤が
配合可能である。特に紫外線吸収剤、紫外線カット剤
（超微粒子酸化チタンや超微粒子酸化亜鉛など）、抗炎
症剤（グリチルリチンジカリウム、グリチルレチン酸な
ど）などを併用すると、一層日焼けによる色素沈着の予
防または回復に効果的である。基剤としては界面活性
剤、増粘剤、保存剤、酸化防止剤、殺菌剤、色素、顔
料、油分、水、アルコール、多価アルコール、香料、防
腐剤、キレート剤などがあげられる。In addition to CPS and placenta extract, the whitening agent for external use of the present invention can be blended with the usual ingredients and bases used for external agents for skin such as cosmetics, quasi drugs and pharmaceuticals. In particular, the combined use of UV absorbers, UV blocking agents (such as ultrafine titanium oxide and ultrafine zinc oxide) and anti-inflammatory agents (such as glycyrrhizin dipotassium and glycyrrhetinic acid) is more effective in preventing or recovering pigmentation due to sunburn. is there. Examples of the base include surfactants, thickeners, preservatives, antioxidants, bactericides, dyes, pigments, oils, water, alcohols, polyhydric alcohols, fragrances, preservatives and chelating agents.
【００１０】本発明の美白外用剤の剤形は、美白化粧料
として薬効を得るのに適したものであればよく、通常の
化粧料、医薬部外品などに用いられる任意の形態、例え
ば、ローション、リニメント、乳液などの外用液剤、ク
リーム、軟膏、ゼリー、被膜剤、ファンデーションなど
の外用半固形剤などを使用することができる。また、そ
れらの製剤を製造する通常の方法により製造することが
できる。The dosage form of the whitening external preparation of the present invention may be any one suitable for obtaining a medicinal effect as a whitening cosmetic, and may be any form used for ordinary cosmetics, quasi drugs, etc., for example, External liquid preparations such as lotions, liniments and emulsions, external semi-solid preparations such as creams, ointments, jellies, coating agents and foundations can be used. In addition, it can be produced by a usual method for producing those preparations.
【００１１】本発明の美白外用剤は１日１回〜数回適量
を肌に塗布することにより使用する。The external whitening agent of the present invention is used by applying an appropriate amount to the skin once to several times a day.
【００１２】[0012]
【発明の効果】本発明の外用剤は、単独で配合すると効
果を示さない化合物を組み合わせることにより、色素沈
着の抑制、皮膚のしみ、そばかすなどの防止または改善
効果を示すので、化粧品、医薬品などへの使用が可能で
ある。EFFECTS OF THE INVENTION The external preparation of the present invention exhibits effects of suppressing pigmentation, preventing or improving skin stains, freckles, etc. by combining compounds which are ineffective when blended alone, therefore, cosmetics, pharmaceuticals, etc. Can be used for.
【００１３】[0013]
【実施例】次に実施例をあげて本発明を詳細に説明す
る。 実施例１ 以下の処方により常法に従って外用剤を調製した。Next, the present invention will be described in detail with reference to examples. Example 1 An external preparation was prepared according to a conventional method according to the following formulation.
【００１４】 ＣＰＳ ０．５（重量％） グリセリン ９．０ ＢＨＴ ０．１ イソプロピルメチルフェノール ０．１ ウシ胎盤抽出液 １０．０ モノステアリン酸ポリオキシ エチレングリコール（４０Ｅ．Ｏ．） ２．０ モノステアリン酸グリセリル ５．０ ステアリン酸 ５．０ コレステリル−１２− ヒドロキシステアレート ３．０ スクワラン １０．０ メチルパラベン ０．１ ブチルパラベン ０．１ メチルセルロース ０．２ グリチルリチンＫ２ ０．２ 精製水 計１００．０。CPS 0.5 (% by weight) Glycerin 9.0 BHT 0.1 Isopropylmethylphenol 0.1 Bovine placenta extract 10.0 Polyoxymonostearate polyoxyethylene glycol (40EO) 2.0 Monostearic acid Glyceryl 5.0 Stearic acid 5.0 Cholesteryl-12-hydroxystearate 3.0 Squalane 10.0 Methylparaben 0.1 Butylparaben 0.1 Methylcellulose 0.2 Glycyrrhizin K2 0.2 Purified water 100.0 in total.
【００１５】実施例２ 以下の処方により常法に従って外用剤を調製した。Example 2 An external preparation was prepared according to a conventional method according to the following formulation.
【００１６】 ＣＰＳ ０．３（重量％） １，３−ブチレングリコール ２．０ ポリオキシエチレン 硬化ヒマシ油 １．５ ヒト胎盤抽出液 ８．０ エチルアルコール ２０．０ クエン酸ナトリウム １．５ 精製水 計１００．０。CPS 0.3 (wt%) 1,3-butylene glycol 2.0 polyoxyethylene hydrogenated castor oil 1.5 human placenta extract 8.0 ethyl alcohol 20.0 sodium citrate 1.5 purified water meter 100.0.
【００１７】実施例３ 以下の処方により常法に従って外用剤を調製した。Example 3 An external preparation was prepared by the usual method according to the following formulation.
【００１８】 ＣＰＳ ０．３（重量％） ヒト胎盤抽出液 ７．０ ジプロピレングリコール ３．０ ポリオキシエチレンソルビタン モノラウリン酸エステル（２０Ｅ．Ｏ．） ３．０ エチルアルコール ５．０ 乳酸ナトリウム １．０ 精製水 全１００．０。CPS 0.3 (wt%) Human placenta extract 7.0 Dipropylene glycol 3.0 Polyoxyethylene sorbitan monolaurate (20EO) 3.0 Ethyl alcohol 5.0 Sodium lactate 1.0 Purified water 100.0.
【００１９】実施例４ 以下の処方により常法に従って外用剤を調製した。Example 4 An external preparation was prepared by the following method according to a conventional method.
【００２０】 ＣＰＳ ０．５（重量％） グリセリン ２．０ ＢＨＴ ０．１ イソプロピルメチルフェノール ０．１ ヒト胎盤抽出液 ８．０ モノステアリン酸ポリオキシ エチレングリコール（４０Ｅ．Ｏ．） ２．０ モノステアリン酸グリセリル ５．０ ステアリン酸 ５．０ コレステリル−１２− ヒドロキシステアレート ３．０ スクワラン １０．０ 超微粒子酸化チタン １０．０ メチルパラベン ０．１ ブチルパラベン ０．１ メチルセルロース ０．２ グリチルリチンＫ２ ０．２ 精製水 全１００．０。CPS 0.5 (wt%) Glycerin 2.0 BHT 0.1 Isopropylmethylphenol 0.1 Human placenta extract 8.0 Polyoxymonostearate Polyoxyethylene glycol (40EO) 2.0 Monostearic acid Glyceryl 5.0 Stearic acid 5.0 Cholesteryl-12-hydroxystearate 3.0 Squalane 10.0 Ultrafine titanium dioxide 10.0 Methylparaben 0.1 Butylparaben 0.1 Methylcellulose 0.2 Glycyrrhizin K2 0.2 Purified water All 100.0.
【００２１】実施例５ 以下の処方により常法に従って外用剤を調製した。Example 5 An external preparation was prepared by the following method according to a conventional method.
【００２２】 ＣＰＳ ０．５（重量％） グリセリン ２．０ ＢＨＴ ０．１ イソプロピルメチルフェノール ０．１ ウシ胎盤抽出液 ７．０ モノステアリン酸ポリオキシ エチレングリコール（４０Ｅ．Ｏ．） ２．０ モノステアリン酸グリセリル ５．０ ステアリン酸 ５．０ コレステリル−１２− ヒドロキシステアレート ３．０ スクワラン １０．０ 超微粒子酸化亜鉛 １０．０ メチルパラベン ０．１ ブチルパラベン ０．１ メチルセルロース ０．２ グリチルリチンＫ２ ０．５ 精製水 全１００．０。CPS 0.5 (% by weight) Glycerin 2.0 BHT 0.1 Isopropylmethylphenol 0.1 Bovine placenta extract 7.0 Polyoxyethylene glycol monostearate (40 EO) 2.0 Monostearic acid Glyceryl 5.0 Stearic acid 5.0 Cholesteryl-12-hydroxystearate 3.0 Squalane 10.0 Ultrafine zinc oxide 10.0 Methylparaben 0.1 Butylparaben 0.1 Methylcellulose 0.2 Glycyrrhizin K2 0.5 Purified water All 100.0.
【００２３】実施例６ 以下の処方により常法に従って外用剤を調製した。Example 6 An external preparation was prepared according to a conventional method according to the following formulation.
【００２４】 ＣＰＳ ０．２ ヒト胎盤抽出液 ３．５ アラントイン ２．０ スクワラン １．０ ステアリルアルコール ０．２ ポリオキシエチレン硬化ヒマシ油 ポリオキシエチレンソルビタン ２．０ モノステアレート ０．５ クエン酸ナトリウム ２．０ パラベン ０．２ プロピレングリコール ５．０ エタノール ２０．０ 精製水 全１００．０。CPS 0.2 Human placental extract 3.5 Allantoin 2.0 Squalane 1.0 Stearyl alcohol 0.2 Polyoxyethylene hydrogenated castor oil Polyoxyethylene sorbitan 2.0 Monostearate 0.5 Sodium citrate 2 0.0 Paraben 0.2 Propylene glycol 5.0 Ethanol 20.0 Purified water Total 100.0.
【００２５】実施例７ 以下の処方により常法に従って外用剤を調製した。Example 7 An external preparation was prepared according to a conventional method according to the following formulation.
【００２６】 ＣＰＳ ０．５（重量％） グリセリン ２．０ ＢＨＴ ０．１ イソプロピルメチルフェノール ０．１ ウシ胎盤抽出液 １０．０ モノステアリン酸ポリオキシ エチレングリコール（４０Ｅ．Ｏ．） ２．０ モノステアリン酸グリセリル ５．０ ステアリン酸 ５．０ コレステリル−１２− ヒドロキシステアレート ３．０ スクワラン １０．０ メチルパラベン ０．１ ブチルパラベン ０．１ メチルセルロース ０．２ グリチルリチンＫ２ ０．８ 精製水 全１００．０。CPS 0.5 (% by weight) Glycerin 2.0 BHT 0.1 Isopropylmethylphenol 0.1 Bovine placenta extract 10.0 Polyoxy monostearate Ethylene glycol (40 EO) 2.0 Monostearic acid Glyceryl 5.0 Stearic acid 5.0 Cholesteryl-12-hydroxystearate 3.0 Squalane 10.0 Methylparaben 0.1 Butylparaben 0.1 Methylcellulose 0.2 Glycyrrhizin K2 0.8 Purified water Total 100.0.
【００２７】試験例１ 有色モルモットの背部を剪毛し、紫外線を照射すると色
素沈着を生じることを利用して、被検物質の美白効果を
検討した。試験は各処方５匹のモルモットを用いて行
い、紫外線照射は、東芝製ＦＬ２０Ｓランプを使用し
た。麻酔下紫外線を照射し、紫外線量は１０ｍＪ／ｃｍ
2とした。紫外線照射の２４時間前と照射直後より４週
間に渡りモルモットの背部４箇所に１日２回、表１に示
す処方の薬剤を１匹につき０．２ｍｌづつ塗布した。紫
外線照射４週間後に各部位の色素沈着の程度を肉眼評価
基準により対照処方群（基剤群）と比較した。評価基準
は、変化無し：０点、軽度改善：０．５点、明確に改
善：１．０点、著しく改善：２．０点の基準で評価し
た。各処方の平均点を表１に示す。なお、紫外線照射直
後には色素沈着に各処方間で差は見られなかった。Test Example 1 The whitening effect of the test substance was examined by utilizing the fact that the back of a colored guinea pig was shaved and irradiated with ultraviolet rays to cause pigmentation. The test was carried out using 5 guinea pigs of each prescription, and the FL20S lamp manufactured by Toshiba was used for ultraviolet irradiation. Irradiate ultraviolet rays under anesthesia, and the amount of ultraviolet rays is 10 mJ / cm
2 0.2 ml of each drug of the formulation shown in Table 1 was applied twice a day to four places on the back of the guinea pig 24 hours before the ultraviolet irradiation and immediately after the irradiation for 4 weeks. Four weeks after ultraviolet irradiation, the degree of pigmentation at each site was compared with the control prescription group (base group) by the visual evaluation standard. The evaluation criteria were as follows: no change: 0 point, slight improvement: 0.5 point, clear improvement: 1.0 point, and marked improvement: 2.0 point. Table 1 shows the average score of each prescription. Immediately after irradiation with ultraviolet rays, no difference was observed in pigmentation between the formulations.
【００２８】[0028]
【表１】 [Table 1]
【００２９】また、各処方について皮膚刺激性試験も行
ったが、いずれの処方も皮膚刺激は確認されなかった。A skin irritation test was also conducted on each formulation, but no skin irritation was confirmed in any formulation.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ａ６１Ｋ 35/50 ＡＤＡ Ａ６１Ｋ 35/50 ＡＤＡ (72)発明者 漆崎 文男 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 (72)発明者 前田 達男 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification number Reference number within the agency FI Technical indication location A61K 35/50 ADA A61K 35/50 ADA (72) Inventor Fumio Urushizaki 3-24 Takada, Toshima-ku, Tokyo No. 1 in Taisho Pharmaceutical Co., Ltd. (72) Inventor Tatsuo Maeda 3-24-1 Takada, Toshima-ku, Tokyo Inside Taisho Pharmaceutical Co., Ltd.
Claims (2)
ラセンタエキスを配合することを特徴とする美白外用
剤。1. A whitening agent for external use characterized by containing chondroitin polysulfate and placenta extract.
１〜５重量％、プラセンタエキスを０．１〜２０重量％
含有する請求項１記載の美白外用剤。2. A chondroitin polysulfate of 0.0
1-5% by weight, placenta extract 0.1-20% by weight
The whitening external preparation according to claim 1, which is contained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8179712A JPH0995421A (en) | 1995-07-24 | 1996-07-10 | Beautifier for external use |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18719495 | 1995-07-24 | ||
| JP7-187194 | 1995-07-24 | ||
| JP8179712A JPH0995421A (en) | 1995-07-24 | 1996-07-10 | Beautifier for external use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0995421A true JPH0995421A (en) | 1997-04-08 |
Family
ID=26499483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8179712A Pending JPH0995421A (en) | 1995-07-24 | 1996-07-10 | Beautifier for external use |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0995421A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016130224A (en) * | 2015-01-13 | 2016-07-21 | 小林製薬株式会社 | External composition |
| JP2016179958A (en) * | 2015-03-24 | 2016-10-13 | 小林製薬株式会社 | Skin pigmentation inhibitor |
-
1996
- 1996-07-10 JP JP8179712A patent/JPH0995421A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016130224A (en) * | 2015-01-13 | 2016-07-21 | 小林製薬株式会社 | External composition |
| JP2016179958A (en) * | 2015-03-24 | 2016-10-13 | 小林製薬株式会社 | Skin pigmentation inhibitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4593046A (en) | Method of reducing skin irritation from benzoyl peroxide | |
| JP3483988B2 (en) | Skin preparation | |
| JP2008526963A (en) | Compositions and methods for treating overpigmented skin | |
| US20090137534A1 (en) | Skin treatment compositions and methods | |
| CN110709077A (en) | Skin treatment method | |
| US20060159714A1 (en) | Use of an antioxidant in a dermatological and/or cosmetic composition | |
| JP2764510B2 (en) | Whitening cosmetics | |
| JP2008510805A (en) | Cosmetic composition comprising certain cyclohexane mono-, di- or triol, or cyclohexylmethane, ethane or propanol | |
| US11918666B2 (en) | Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment | |
| JPH10114648A (en) | Composition for external use for skin | |
| US4055662A (en) | Antimicrobial composition containing 10-undecensic acid isopropylic ester | |
| JP2787404B2 (en) | External preparation for skin | |
| JPH11139951A (en) | Cosmetic | |
| JPH11100324A (en) | Composition for treating pimple | |
| JPH08104635A (en) | External pharmaceutical preparation containing zinc phytate as active ingredient | |
| JPH1036246A (en) | Suppressant for melanogenesis and preparation for external use for skin | |
| JPH0725660B2 (en) | Cosmetics with anti-inflammatory properties against sunburn | |
| JPH0995421A (en) | Beautifier for external use | |
| JPH06172150A (en) | Skin cosmetic | |
| CN114306107A (en) | Functional skin product and preparation method thereof | |
| JP2001270828A (en) | External preparation for prevention and therapy of vulgaris acne and cosmetic prepared by formulating the same | |
| JP2002234828A (en) | Skin whitening cosmetic preparation | |
| KR101661694B1 (en) | Low irritating composition for skin whitening comprising hydroquinone | |
| JPH0952817A (en) | Beautifying and whitening cosmetic | |
| JP2506388B2 (en) | Topical skin |